{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:26:29Z","timestamp":1783416389231,"version":"3.54.6"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1R21AI137932-01A1"],"award-info":[{"award-number":["1R21AI137932-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Molecular Mechanisms of Combination Adjuvants","award":["1U01AI124284-01"],"award-info":[{"award-number":["1U01AI124284-01"]}]},{"name":"Adjuvant Discovery","award":["HHSN272201400052C"],"award-info":[{"award-number":["HHSN272201400052C"]}]},{"name":"Adjuvant Discovery","award":["75N93019C00044"],"award-info":[{"award-number":["75N93019C00044"]}]},{"name":"Development","award":["HHSN272201800047C"],"award-info":[{"award-number":["HHSN272201800047C"]}]},{"name":"Program Contracts, Development of Vaccines","award":["75N93020C00038"],"award-info":[{"award-number":["75N93020C00038"]}]},{"name":"Human Immunology Project Consortium","award":["U19AI118608-01A1"],"award-info":[{"award-number":["U19AI118608-01A1"]}]},{"name":"Adjuvant Discovery Program","award":["75N93019C00044"],"award-info":[{"award-number":["75N93019C00044"]}]},{"name":"Development of Vaccines","award":["75N93020C00038"],"award-info":[{"award-number":["75N93020C00038"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused significant mortality, especially among older adults whose distinct immune system reflects immunosenescence. Multiple SARS-CoV-2 vaccines have received emergency use authorization and\/or licensure from the US Food and Drug Administration and throughout the world. However, their deployment has heighted significant limitations, such by age-dependent immunogenicity, requirements for multiple vaccine doses, refrigeration infrastructure that is not universally available, as well as waning immunity. Thus, there was, and continues to be a need for continued innovation during the pandemic given the desire for dose-sparing, formulations stable at more readily achievable temperatures, need for robust immunogenicity in vulnerable populations, and development of safe and effective pediatric vaccines. In this context, optimal SARS-CoV-2 vaccines may ultimately rely on inclusion of adjuvants as they can potentially enhance protection of vulnerable populations and provide dose-sparing effects enabling single shot protection.<\/jats:p>","DOI":"10.1093\/cid\/ciac342","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T11:13:22Z","timestamp":1651490002000},"page":"S30-S36","source":"Crossref","is-referenced-by-count":9,"title":["A Precision Adjuvant Approach to Enhance Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines Optimized for Immunologically Distinct Vulnerable Populations"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1095-6156","authenticated-orcid":false,"given":"David J","family":"Dowling","sequence":"first","affiliation":[{"name":"Precision Vaccines Program"},{"name":"Division of Infectious Diseases, Boston Children\u2019s Hospital , Boston, Massachusetts , USA"},{"name":"Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Levy","sequence":"additional","affiliation":[{"name":"Precision Vaccines Program"},{"name":"Division of Infectious Diseases, Boston Children\u2019s Hospital , Boston, Massachusetts , USA"},{"name":"Harvard Medical School , Boston, Massachusetts , USA"},{"name":"Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"2022081503572513900_ciac342-B1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"key":"2022081503572513900_ciac342-B2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"2022081503572513900_ciac342-B3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"N Engl J Med"},{"key":"2022081503572513900_ciac342-B4","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2022081503572513900_ciac342-B5","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2022081503572513900_ciac342-B6","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"key":"2022081503572513900_ciac342-B7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.it.2014.04.007","article-title":"Ontogeny of early life immunity","volume":"35","author":"Dowling","year":"2014","journal-title":"Trends Immunol"},{"key":"2022081503572513900_ciac342-B8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.it.2008.12.001","article-title":"Variation matters: TLR structure and species-specific pathogen recognition","volume":"30","author":"Werling","year":"2009","journal-title":"Trends Immunol"},{"key":"2022081503572513900_ciac342-B9","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1016\/j.vaccine.2017.07.062","article-title":"Personalized vaccinology: a review","volume":"36","author":"Poland","year":"2018","journal-title":"Vaccine"},{"key":"2022081503572513900_ciac342-B10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/cid\/cit209","article-title":"Heterologous (\u201cnonspecific\u201d) and sex-differential effects of vaccines: epidemiology, clinical trials, and emerging immunologic mechanisms","volume":"57","author":"Flanagan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022081503572513900_ciac342-B11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"2022081503572513900_ciac342-B12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/trstmh\/tru167","article-title":"Sex-based differences in immune function and responses to vaccination","volume":"109","author":"Klein","year":"2015","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2022081503572513900_ciac342-B13","doi-asserted-by":"crossref","first-page":"103998","DOI":"10.1016\/j.cellimm.2019.103998","article-title":"Aging and influenza vaccine-induced immunity","volume":"348","author":"Dugan","year":"2020","journal-title":"Cell Immunol"},{"key":"2022081503572513900_ciac342-B14","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1080\/21645515.2017.1405200","article-title":"Effects of influenza immunization on pneumonia in the elderly","volume":"14","author":"Heo","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2022081503572513900_ciac342-B15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12979-017-0107-2","article-title":"Vaccines for the elderly: current use and future challenges","volume":"15","author":"Weinberger","year":"2018","journal-title":"Immun Ageing"},{"key":"2022081503572513900_ciac342-B16","first-page":"1","article-title":"Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review","volume":"3","author":"Nanishi","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"2022081503572513900_ciac342-B17","first-page":"590373","article-title":"Towards precision vaccines: lessons from the second international precision vaccines conference","volume-title":"Front Immunol","author":"Soni","year":"2020"},{"key":"2022081503572513900_ciac342-B18","doi-asserted-by":"crossref","first-page":"662218","DOI":"10.3389\/fimmu.2021.662218","article-title":"Precision vaccine development: cues from natural immunity","volume":"12","author":"Barman","year":"2022","journal-title":"Front Immunol"},{"key":"2022081503572513900_ciac342-B19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4049\/immunohorizons.1700063","article-title":"Recent advances in the discovery and delivery of TLR7\/8 agonists as vaccine adjuvants","volume":"2","author":"Dowling","year":"2018","journal-title":"Immuno Horizons"},{"key":"2022081503572513900_ciac342-B20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MOP.0000000000000868","article-title":"Toward precision adjuvants: optimizing science and safety","volume":"32","author":"Nanishi","year":"2020","journal-title":"Curr Opin Pediatr"},{"key":"2022081503572513900_ciac342-B21","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat Med"},{"key":"2022081503572513900_ciac342-B22","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.4049\/jimmunol.1600282","article-title":"Age-specific adjuvant synergy: dual TLR7\/8 and mincle activation of human newborn dendritic cells enables Th1 polarization","volume":"197","author":"van Haren","year":"2016","journal-title":"J Immunol"},{"key":"2022081503572513900_ciac342-B23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.coph.2018.03.014","article-title":"Adjuvant strategies to improve vaccination of the elderly population","volume":"41","author":"Weinberger","year":"2018","journal-title":"Curr Opinion Pharmacol"},{"key":"2022081503572513900_ciac342-B24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.immuni.2012.10.014","article-title":"Innate immune function by toll-like receptors: distinct responses in newborns and the elderly","volume":"37","author":"Kollmann","year":"2012","journal-title":"Immunity"},{"key":"2022081503572513900_ciac342-B25","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/INF.0000000000000893","article-title":"Pediatric vaccine adjuvants: components of the modern vaccinologist\u2019s toolbox","volume":"34","author":"Dowling","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"2022081503572513900_ciac342-B26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1586\/14760584.2.2.305","article-title":"CpG DNA as a vaccine adjuvant","volume":"2","author":"Klinman","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"2022081503572513900_ciac342-B27","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0264-410X(99)00526-5","article-title":"CpG DNA induces stronger immune responses with less toxicity than other adjuvants","volume":"18","author":"Weeratna","year":"2000","journal-title":"Vaccine"},{"key":"2022081503572513900_ciac342-B28","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.4049\/jimmunol.175.3.1619","article-title":"CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells","volume":"175","author":"Roda","year":"2005","journal-title":"J Immunol"},{"key":"2022081503572513900_ciac342-B29","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.vaccine.2012.01.087","article-title":"Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18\u201355 years of age","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"2022081503572513900_ciac342-B30","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1016\/j.vaccine.2013.05.068","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age","volume":"31","author":"Heyward","year":"2013","journal-title":"Vaccine"},{"key":"2022081503572513900_ciac342-B31","article-title":"NIAID Strategic Plan for Research on Vaccine Adjuvants.","author":"National Institute of Health","year":"2018"},{"key":"2022081503572513900_ciac342-B32","first-page":"e91020","article-title":"TLR7\/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth","volume-title":"JCI Insight","author":"Dowling","year":"2017"},{"key":"2022081503572513900_ciac342-B33","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jaci.2016.12.985","article-title":"Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses","volume":"140","author":"Dowling","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2022081503572513900_ciac342-B34","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1074\/mcp.M115.055541","article-title":"Adjuvant-induced human monocyte secretome profiles reveal adjuvant- and age-specific protein signatures","volume":"15","author":"Oh","year":"2016","journal-title":"Mol Cell Proteomics"},{"key":"2022081503572513900_ciac342-B35","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3389\/fimmu.2016.00562","article-title":"A meningococcal outer membrane vesicle vaccine incorporating genetically attenuated endotoxin dissociates inflammation from immunogenicity","volume":"7","author":"Dowling","year":"2016","journal-title":"Front Immunol"},{"key":"2022081503572513900_ciac342-B36","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.3389\/fimmu.2018.02634","article-title":"Microphysiologic human tissue constructs reproduce autologous age-specific BCG and HBV primary immunization in vitro","volume":"9","author":"Sanchez-Schmitz","year":"2018","journal-title":"Front Immunol"},{"key":"2022081503572513900_ciac342-B37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jaci.2012.02.042","article-title":"Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways","volume":"130","author":"Philbin","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"2022081503572513900_ciac342-B38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fimmu.2014.00457","article-title":"Soluble mediators regulating immunity in early life","volume":"5","author":"Pettengill","year":"2014","journal-title":"Front Immunol"},{"key":"2022081503572513900_ciac342-B39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cyto.2016.04.001","article-title":"In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant","volume":"83","author":"van Haren","year":"2016","journal-title":"Cytokine"},{"key":"2022081503572513900_ciac342-B40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/imr.12889","article-title":"Modulation of immune responses using adjuvants to facilitate therapeutic vaccination","volume":"296","author":"Schijns","year":"2020","journal-title":"Immunol Rev"},{"key":"2022081503572513900_ciac342-B41","doi-asserted-by":"crossref","first-page":"106717","DOI":"10.1016\/j.intimp.2020.106717","article-title":"Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses","volume":"86","author":"Gupta","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2022081503572513900_ciac342-B42","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/cmi.2015.03","article-title":"Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus","volume":"13","author":"Zhang","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"2022081503572513900_ciac342-B43","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.vaccine.2017.02.012","article-title":"MERS-CoV spike nanoparticles protect mice from MERS-CoV infection","volume":"35","author":"Coleman","year":"2017","journal-title":"Vaccine"},{"key":"2022081503572513900_ciac342-B44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"2022081503572513900_ciac342-B45","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-020-0358-6","article-title":"COVID-19 vaccines: neutralizing antibodies and the alum advantage","volume":"20","author":"Hotez","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2022081503572513900_ciac342-B46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNgamma response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines"},{"key":"2022081503572513900_ciac342-B47","doi-asserted-by":"crossref","first-page":"20085","DOI":"10.1038\/s41598-020-77077-z","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci Rep"},{"key":"2022081503572513900_ciac342-B48","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"2022081503572513900_ciac342-B49","doi-asserted-by":"crossref","first-page":"e02648","DOI":"10.1128\/mBio.02648-20","article-title":"Introduction of two prolines and removal of the polybasic cleavage site lead to higher efficacy of a recombinant spike-based SARS-CoV-2 vaccine in the mouse model","volume":"12","author":"Amanat","year":"2021","journal-title":"mBio"},{"key":"2022081503572513900_ciac342-B50","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 Trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"key":"2022081503572513900_ciac342-B51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41390-020-01112-y","article-title":"The sixth revolution in pediatric vaccinology: immunoengineering and delivery systems","volume":"89","author":"Soni","year":"2021","journal-title":"Pediatr Res"},{"key":"2022081503572513900_ciac342-B52","doi-asserted-by":"crossref","first-page":"eabj5305","DOI":"10.1126\/scitranslmed.abj5305","article-title":"An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice","volume":"14","author":"Nanishi","year":"2022","journal-title":"Sci Transl Med"},{"key":"2022081503572513900_ciac342-B53","author":"CTRI","year":"2020"},{"key":"2022081503572513900_ciac342-B54","author":"DFC","year":"2021"},{"key":"2022081503572513900_ciac342-B55","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.cell.2022.01.009","article-title":"An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity","volume":"185","author":"Borriello","year":"2022","journal-title":"Cell"},{"key":"2022081503572513900_ciac342-B56","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.09.45966","article-title":"An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice","volume-title":"BioRxiv","author":"Borriello","year":"2021"},{"key":"2022081503572513900_ciac342-B57","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1006\/jmbi.2000.4435","article-title":"X-ray structure analysis and crystallographic refinement of lumazine synthase from the hyperthermophile Aquifex aeolicus at 1.6 A resolution: determinants of thermostability revealed from structural comparisons","volume":"306","author":"Zhang","year":"2001","journal-title":"J Mol Biol"},{"key":"2022081503572513900_ciac342-B58","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1016\/j.vaccine.2017.04.055","article-title":"Carbohydrate fatty acid monosulphate esters are safe and effective adjuvants for humoral responses","volume":"35","author":"Hilgers","year":"2017","journal-title":"Vaccine"},{"key":"2022081503572513900_ciac342-B59","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.vaccine.2004.07.021","article-title":"Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition","volume":"23","author":"Blom","year":"2004","journal-title":"Vaccine"},{"key":"2022081503572513900_ciac342-B60","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"2022081503572513900_ciac342-B61","article-title":"mRNA booster vaccination protects extremely aged mice against the SARS-CoV-2 Omicron variant","author":"Dowling","year":"2022","journal-title":"Research Square"},{"key":"2022081503572513900_ciac342-B62","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41590-018-0052-z","article-title":"Toll-like receptor 9 antagonizes antibody affinity maturation","volume":"19","author":"Akkaya","year":"2018","journal-title":"Nat Immunol"},{"key":"2022081503572513900_ciac342-B63","doi-asserted-by":"publisher","first-page":"ciac302","DOI":"10.1093\/cid\/ciac302","article-title":"Precision vaccine adjuvants for older adults: a scoping review","author":"Nanishi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2022081503572513900_ciac342-B64","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0140-6736(20)31558-0","article-title":"Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study","volume":"396","author":"de Figueiredo","year":"2020","journal-title":"Lancet"},{"key":"2022081503572513900_ciac342-B65","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-019-1656-7","article-title":"Immunization: vital progress, unfinished agenda","volume":"575","author":"Piot","year":"2019","journal-title":"Nature"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac342\/43540623\/ciac342.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/Supplement_1\/S30\/45407551\/ciac342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/Supplement_1\/S30\/45407551\/ciac342.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T03:59:10Z","timestamp":1660535950000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/Supplement_1\/S30\/6580093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":65,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2022,5,4]]},"published-print":{"date-parts":[[2022,8,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac342","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,15]]},"published":{"date-parts":[[2022,5,4]]}}}